Combination Use Of Targeted Cancer Therapies Advancing Since ASCO, Roche Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The debate surrounding the cost of novel cancer treatments can be validated by "solid data," Roche Pharmaceuticals Head Burns says. The firm is confident that the positioning of its products, including Genentech's Avastin, is "defensible."